Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis

Wednesday, June 1, 2011 General News J E 4
- Plenary presentation of Phase III study examining benefit of extended adjuvant treatment with Gleevec® for three years vs. one year for patients with KIT+ GIST

Novartis Media Relations

Media only:

Investors only:

Gloria Vanderham

Richard Jarvis

Novartis Oncology

Novartis Corporation

P: +1 862 778 4268

P: +1 212 830 2433

Dana Kahn Cooper

P: +1 732 817 1800

F: +1 732 817 1834



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Cell Therapeutics Regains Compliance with NASDAQ M...
Global Sleep Apnea Diagnostic And Therapeutic Devi...